Natalie Ee Mun Leong

CIK: 0001959318

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

QNRX

Quoin Pharmaceuticals, Ltd.

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

QNRX
Quoin Pharmaceuticals, Ltd.
Feb 4, 2026
Award(A)
Share Option (Right to Buy)
Direct
12.2K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Aug 21, 2025
Award(A)
Share Option (Right to Buy)
Direct
4.1K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
May 29, 2025
Award(A)
Share Option (Right to Buy)
Direct
7.8K shares-
QNRX
Quoin Pharmaceuticals, Ltd.
Dec 9, 2024
Award(A)
Share Option (Right to Buy)
Direct
50.7K shares-

		Type	Shares	Price		Ownership
Feb 4, 2026	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	12,211	-	-	Direct
Aug 21, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	4,105	-	-	Direct
May 29, 2025	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	7,760	-	-	Direct
Dec 9, 2024	QNRX Quoin Pharmaceuticals, Ltd.	Award(A) Share Option (Right to Buy)	50,714	-	-	Direct

1-4 of 4 transactions

About Leong Natalie Ee Mun

Leong Natalie Ee Mun (SEC CIK 0001959318) files insider reports with the SEC as Director of Quoin Pharmaceuticals, Ltd. (QNRX).

Signal8 holds 4 ownership filings by Leong Natalie Ee Mun, all Form 4s, filed between Dec 10, 2024 and Feb 6, 2026. Those filings report 4 transactions, from Dec 9, 2024 to Feb 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Leong Natalie Ee Mun's filings is in ASHBURN, VA.

Recent filings by Leong Natalie Ee Mun

Feb 4, 2026: Grant or award of QNRX derivative securities (Form 4, code A).
Aug 21, 2025: Grant or award of QNRX derivative securities (Form 4, code A).
May 29, 2025: Grant or award of QNRX derivative securities (Form 4, code A).
Dec 9, 2024: Grant or award of QNRX derivative securities (Form 4, code A).

Other insiders filing for Quoin Pharmaceuticals, Ltd. (QNRX)

LANGER DENNIS, Director
Carter Denise P., Chief Operating Officer
Myers Michael, Chief Executive Officer
Lawlor Sally Bridget, Chief Financial Officer
Culverwell Anthony James, Director
Cooper Joseph Patrick, Director

How to read Form 4 transaction codes